Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today said that the Data Safety Monitoring Board (DSMB) of the
IMPROVE-IT trial has completed its planned review of study data and
recommended that the study continue.
The study design calls for the collection of 5,250 clinical endpoints.
Merck remains blinded to the actual results of this analysis and to
other IMPROVE-IT safety and efficacy data.
Language:
English
Contact HTML:
MerckMedia:Kelley Dougherty, 908-423-4291Skip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more